Stem Cell Transplantation
Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.
Comparison study demonstrates early response and survival benefits of VTD, VTDC, and TAD regimens in transplant-eligible patients with newly diagnosed multiple myeloma.
Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab VedotinJune 29, 2017
Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.
Palliative care added to transplant care improved relief from depression and PTSD symptoms following hematopoietic stem cell transplantation.
A nurse-led team developed a tracking tool that created a vaccination schedule from transplant date forward for autologous hematopoietic stem cell transplant recipients.
An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.
Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.
A novel agent, letermovir, reduced incidence of CMV in patients undergoing stem cell transplantation for hematologic malignancies.
Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.
Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.
This fact sheet reviews bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) as they relate to the cancer treatment.
An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.
A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.
Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.
Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.
Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).
Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.
In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.
Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT) significantly prolonged overall survival in patients with multiple myeloma compared with no maintenance, a meta-analysis of 3 randomized controlled trials presented at the 2016 ASCO Annual Meeting has found.
Upfront autologous stem cell transplantation (ASCT) remains the preferred treatment for patients age 65 years or younger with newly diagnosed multiple myeloma, according to phase 3 study results reported at the 2016 ASCO Annual Meeting.
Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical TransplantationApril 25, 2016
Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.
Current presence of pain was associated with both greater depression and fatigue in survivors of hematopoietic stem cell transplantation (HSCT).
Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.
For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.
For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.
Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)November 25, 2015
More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.
A sleep deficit of just 4 hours affects the ability of blood and immune-system stem cells to migrate to the proper spots in the bone marrow of recipient mice and churn out the cell types necessary to reconstitute a damaged immune system by as much as 50%.
High-Dose Chemo and Stem Cell Transplantation Results in Long-Term Survival for Patients With AmyloidosisOctober 27, 2015
Patients with light-chain amyloidosis who are treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival.
Targeting exhausted immune cells may change the prognosis for patients with AML relapse after a stem cell transplant, according to a recent study.
Greatly improved outcomes have been observed in using stem cell transplantation to treat patients with juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|